Table 2 Cohort characteristics of the training and validation cohorts
From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer
Patient clinical characteristics | Training | Validation |
|---|---|---|
n (%) | 268 (65.4) | 140 (34.6) |
Benign | 123 (44) | 59 (41) |
PCa | 145 (52) | 81 (57) |
Gleason score | ||
6 | 60 (41) | 36 (44) |
7 | 55 (38) | 28 (35) |
8–10 | 30 (21) | 17 (21) |
Clinical T stage | ||
T1 | 101 (70) | 48 (59) |
T2 | 25 (17) | 16 (20) |
T3 | 11 (8) | 11 (14) |
T4 | 8 (6) | 6 (7) |
% Biopsy cores positive for PCa | ||
Median | 29% | 33% |
Range | 5–100% | 5–100% |
Interquartile range | 13%–55% | 14%–63% |
N/A | 8 | 6 |
Age at enrollment | ||
Median | 66 | 66 |
Range | 42–85 | 37–85 |
Interquartile range | 59–71 | 59–72 |
PSA at presentation | ||
Median | 6.9 | 7.04 |
Range | 0.01–248 | 0.04–377.00 |
Interquartile range | 4.55–10.36 | 4.79–11 |
Prostate volume | ||
Median | 7 | 49 |
Range | 18.0–121.6 | 18.0–121.6 |
Interquartile range | 39.15–68.68 | 37–65.1 |
N/A | 114 | 58 |
Perineural invasion | ||
Yes | 30 | 13 |
No | 97 | 55 |
N/A | 153 | 75 |
CAPRA risk | ||
CAPRA low | 47 (32) | 33 (41) |
CAPRA intermediate | 56 (39) | 26 (32) |
CAPRA high | 42 (29) | 22 (27) |
D’Amico risk | ||
D’Amico low | 41 (28) | 28 (35) |
D’Amico intermediate | 57 (39) | 24 (30) |
D’Amico high | 47 (32) | 29 (36) |